Selvita to Present a Poster on the Developments of Its Oncology Program During the 2009 AACR-NCI-EORTC International Conference
Kraków, Poland, November 18, 2009 --(PR.com)-- Selvita Ltd. announced that it will present a poster on the company's investigational compounds during the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which will be held on November 15-19, 2009 in Boston, MA, USA.
Selvita will present the poster # A242, titled “Identification of novel and specific Pim-1 kinase inhibitors with potent anticancer activity in hematological and solid tumor malignancies”, which reports on the results of a lead optimization study of a new small molecule Pim-1 kinase inhibitor - SEL24-1.
Dr. Nicolas Beuzen, Selvita’s CSO commented: “In order to improve the potency and selectivity of the original compound, a series of new derivatives was synthesized and screened for Pim-1 inhibition. Among the newly synthesized compounds several exerted increased potency in Pim-1 inhibition with IC50 values below 5 nM. We are very enthusiastic about this progress and present here and discuss full results of the optimization efforts ,which clearly support further development of this class of inhibitors in oncology indications.”
This poster will be displayed during the Poster Session A on Therapeutic Agents: Small Molecule Kinase Inhibitors, on Monday November 16, 2009, between 12:30 PM - 2:30 PM.
About Selvita
Selvita delivers comprehensive solutions to customers from the pharmaceutical and biotechnology industry targeted at lowering the cost of introducing innovative compounds to the market. The areas of our activity include: advanced protein modeling services and software; computer aided drug design; optimization of lead compounds; contract synthesis; information technology for research projects.
Selvita also conducts its own innovative research projects for the pharmaceuticals customers, in collaboration with various leading research institutions. Currently projects being developed are in the area of oncology and central nervous system.
Media contact:
Natalia Pawela
natalia.pawela@selvita.com
+48 12 6645305
###
Selvita will present the poster # A242, titled “Identification of novel and specific Pim-1 kinase inhibitors with potent anticancer activity in hematological and solid tumor malignancies”, which reports on the results of a lead optimization study of a new small molecule Pim-1 kinase inhibitor - SEL24-1.
Dr. Nicolas Beuzen, Selvita’s CSO commented: “In order to improve the potency and selectivity of the original compound, a series of new derivatives was synthesized and screened for Pim-1 inhibition. Among the newly synthesized compounds several exerted increased potency in Pim-1 inhibition with IC50 values below 5 nM. We are very enthusiastic about this progress and present here and discuss full results of the optimization efforts ,which clearly support further development of this class of inhibitors in oncology indications.”
This poster will be displayed during the Poster Session A on Therapeutic Agents: Small Molecule Kinase Inhibitors, on Monday November 16, 2009, between 12:30 PM - 2:30 PM.
About Selvita
Selvita delivers comprehensive solutions to customers from the pharmaceutical and biotechnology industry targeted at lowering the cost of introducing innovative compounds to the market. The areas of our activity include: advanced protein modeling services and software; computer aided drug design; optimization of lead compounds; contract synthesis; information technology for research projects.
Selvita also conducts its own innovative research projects for the pharmaceuticals customers, in collaboration with various leading research institutions. Currently projects being developed are in the area of oncology and central nervous system.
Media contact:
Natalia Pawela
natalia.pawela@selvita.com
+48 12 6645305
###
Contact
Selvita
Natalia Pawela
+48 12 664 5305
www.selvita.com
Natalia Pawela
+48 12 664 5305
www.selvita.com
Contact
Categories